Maram El-Hussieny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maram El-Hussieny has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Marwa Monier Mahmoud Refaie
Department of Medical Pharmacology, Faculty of Medicine, Minia University, Minia 61511, Egypt
8 shared publications - Asmaa M. A. Bayoumi
Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, 61511, Egypt
3 shared publications - Ahmed Mohamed Okasha
Biochemistry, Minia University Faculty of Medicine, El Minia, Egypt
1 shared publication Enas Mostafa Mohammed
Obstetrics and Gynecology, Minia University Faculty of Medicine, El Minia, Egypt
1 shared publicationManal Abd El Tawab
Pathology Department, Faculty of Medicine, Minia University, El Minia, Egypt
1 shared publicationMarwa Monier Refaie
Department of Pharmacology, Faculty of Medicine, Minia University, Minia, Egypt
1 shared publication
Latest Publications
- Open Access
- 6 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 649
Protective Effects of Irbesartan, an Angiotensin Receptor Blocker with PPARγ Agonistic Activity, against Estradiol Benzoate-Induced Endometrial Hyperplasia and Atypia in Female Rats via Modulation of TNFα/Survivin Pathway
Endometrial hyperplasia (EH) is a common gynecological problem and may progress to carcinoma. Early detection and management of EH are mandatory for the prevention of endometrial cancer. Activation of the renin–angiotensin system and angiotensin II signaling are involved in the progression of precancerous and cancerous lesions. However, no studies have evaluated the role of this system in estradiol benzoate (EB)-induced EH and atypia. Irbesartan (IRB), an angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma (PPARγ) agonistic activity was administered (30 mg/kg/d) in EB-treated (60 µg/100 g bodyweight, intramuscularly, three times per week) or untreated rats for 4 weeks. Uterine weight changes, malondialdehyde, superoxide dismutase (SOD), tumor necrosis factor-alpha (TNFα), survivin, cleaved caspase 3, interleukin-10 (IL10), and PPARγ were measured in addition to undergoing histopathological examination. Results showed that EB-induced EH and atypia significantly increased the uterine body weight, malondialdehyde, TNFα, and survivin, accompanied with significantly decreased SOD, cleaved caspase 3, IL10, and PPARγ, with typical histopathological changes of EH and atypia. Coadministration of IRB significantly prevented EB-induced biochemical and histopathological changes. The protective effects of IRB may be attributed to its anti-inflammatory and antioxidant properties, reduction of survivin, and increased levels of cleaved caspase 3.
- 6 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 649
Open AccessProtective Effects of Irbesartan, an Angiotensin Receptor Blocker with PPARγ Agonistic Activity, against Estradiol Benzoate-Induced Endometrial Hyperplasia and Atypia in Female Rats via Modulation of TNFα/Survivin Pathway
Endometrial hyperplasia (EH) is a common gynecological problem and may progress to carcinoma. Early detection and management of EH are mandatory for the prevention of endometrial cancer. Activation of the renin–angiotensin system and angiotensin II signaling are involved in the progression of precancerous and cancerous lesions. However, no studies have evaluated the role of this system in estradiol benzoate (EB)-induced EH and atypia. Irbesartan (IRB), an angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma (PPARγ) agonistic activity was administered (30 mg/kg/d) in EB-treated (60 µg/100 g bodyweight, intramuscularly, three times per week) or untreated rats for 4 weeks. Uterine weight changes, malondialdehyde, superoxide dismutase (SOD), tumor necrosis factor-alpha (TNFα), survivin, cleaved caspase 3, interleukin-10 (IL10), and PPARγ were measured in addition to undergoing histopathological examination. Results showed that EB-induced EH and atypia significantly increased the uterine body weight, malondialdehyde, TNFα, and survivin, accompanied with significantly decreased SOD, cleaved caspase 3, IL10, and PPARγ, with typical histopathological changes of EH and atypia. Coadministration of IRB significantly prevented EB-induced biochemical and histopathological changes. The protective effects of IRB may be attributed to its anti-inflammatory and antioxidant properties, reduction of survivin, and increased levels of cleaved caspase 3.
- Open Access
- 1 July 2021
- Published by Egyptian Knowledge Bank in Minia Journal of Medical Research
- Vol. 32 (3) , 58-61
Diacerein ameliorates benign prostatic hyperplasia with dysplastic changes in rats via modulation of IL1β and Nrf2/HO1 pathway
Benign prostatic hyperplasia (BPH) is a common disrupting health problem affects elderly men. However, different mechanisms underlying the pathogenesis of BPH are still unclear. For the first time, we tried to explore the role of interleukin 1β (IL1β) antagonist, diacerein (DIA) in BPH and different pathways involved in mediating such effect. BPH was induced using testosterone propionate (TP) (5 mg/kg/day) for 4 weeks subcutaneous injection followed by DIA (50 mg/kg/day) orally for 4 weeks. We evaluated the histopathological changes, prostate weight, dihydrotestosterone (DHT), prostate specific antigen (PSA), and total antioxidant capacity (TAC) in serum. Moreover, malondialdehyde (MDA), heme oxygenase 1 (HO1), nuclear factor erythroid 2–related factor 2 (Nrf2), caspase3, IL1β expressions, and proliferating cell nuclear antigen (PCNA) were measured in tissue specimens. Our results confirmed the induction of BPH by histopathological examination which revealed typical changes of BPH with dysplastic features. Moreover, there are significant increases in prostate weights, DHT, PSA, PCNA, MDA, and IL1β but significant decreases in TAC, HO1, Nrf2 and caspase 3. Interestingly, DIA significantly improved BPH induced histopathological and biochemical changes that is not differing from control group without dysplastic changes. This is mostly attributed to blocking of IL1β, anti-oxidant, apoptotic properties with activation of Nrf2/HO1 pathway.
- 1 July 2021
- Published by Egyptian Knowledge Bank in Minia Journal of Medical Research
- Vol. 32 (3) , 58-61
Open AccessDiacerein ameliorates benign prostatic hyperplasia with dysplastic changes in rats via modulation of IL1β and Nrf2/HO1 pathway
Benign prostatic hyperplasia (BPH) is a common disrupting health problem affects elderly men. However, different mechanisms underlying the pathogenesis of BPH are still unclear. For the first time, we tried to explore the role of interleukin 1β (IL1β) antagonist, diacerein (DIA) in BPH and different pathways involved in mediating such effect. BPH was induced using testosterone propionate (TP) (5 mg/kg/day) for 4 weeks subcutaneous injection followed by DIA (50 mg/kg/day) orally for 4 weeks. We evaluated the histopathological changes, prostate weight, dihydrotestosterone (DHT), prostate specific antigen (PSA), and total antioxidant capacity (TAC) in serum. Moreover, malondialdehyde (MDA), heme oxygenase 1 (HO1), nuclear factor erythroid 2–related factor 2 (Nrf2), caspase3, IL1β expressions, and proliferating cell nuclear antigen (PCNA) were measured in tissue specimens. Our results confirmed the induction of BPH by histopathological examination which revealed typical changes of BPH with dysplastic features. Moreover, there are significant increases in prostate weights, DHT, PSA, PCNA, MDA, and IL1β but significant decreases in TAC, HO1, Nrf2 and caspase 3. Interestingly, DIA significantly improved BPH induced histopathological and biochemical changes that is not differing from control group without dysplastic changes. This is mostly attributed to blocking of IL1β, anti-oxidant, apoptotic properties with activation of Nrf2/HO1 pathway.
- 11 November 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 40 (3) , 222-232
Possible Role of TGF-β1, MMP-2, E-CAD, β-Catenin and Antioxidants in Pathogenesis of Placenta Accreta
Placenta accreta (PA) can be life-threatening due to postpartum hemorrhage and may lead to cesarean hysterectomy. We investigated the expression of Matrix metalloproteinase-2 (MMP-2), β-catenin, E-...
- 11 November 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 40 (3) , 222-232
Possible Role of TGF-β1, MMP-2, E-CAD, β-Catenin and Antioxidants in Pathogenesis of Placenta Accreta
Placenta accreta (PA) can be life-threatening due to postpartum hemorrhage and may lead to cesarean hysterectomy. We investigated the expression of Matrix metalloproteinase-2 (MMP-2), β-catenin, E-...
- 1 August 2019
- Published by Elsevier in Environmental Toxicology and Pharmacology
- Vol. 70, 103198
Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway
- 1 August 2019
- Published by Elsevier in Environmental Toxicology and Pharmacology
- Vol. 70, 103198
Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway
- 22 June 2019
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 20 (1) , 71-81
Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity
Cyclophosphamide (CP) is a widely used chemotherapeutic agent but its clinical usefulness is challenged with different forms of toxicities. No studies have evaluated the possible protective effect of nicorandil (NIC) in CP-induced cardiotoxicity. Our study aimed to investigate this effect by using NIC (3 mg/kg/day) orally for 5 days, in the presence or absence of cardiotoxicity induced by intraperitoneal (i.p.) injection of CP (150 mg/kg) on 4th and 5th days. We confirmed the role of ATP-sensitive potassium channel (KATP) by coadministration of glibenclamide (GP) (5 mg/kg/day) 2 h before NIC (3 mg/kg/day) for 5 days. Moreover, the role of endothelial nitric oxide synthase (eNOS) was confirmed by coadministration of nitro-ω-l-arginine (l-NNA) (25 mg/kg/day) for 5 days. Results showed that CP succeeded in induction of cardiotoxicity which manifested by a significant increase in heart weights, creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), troponin I, cardiac tissue malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), interleukin 1β (IL1 β), and caspase-3 levels. Furthermore, CP group showed toxic histopathological changes of marked cardiac damage in addition to a significant decrease in total antioxidant capacity (TAC), superoxide dismutase (SOD), eNOS gene expression, and B cell lymphoma 2 (Bcl2) immunoexpression. NIC succeeded in reversing CP-induced cardiotoxicity by its potassium channel opening effect, stimulating eNOS gene expression, anti-inflammatory, antiapoptotic, and antioxidant properties. Coadministration of GP or l-NNA could diminish the protective effect of NIC. This proves the important role of KATP and eNOS in mediating such protection.
- 22 June 2019
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 20 (1) , 71-81
Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity
Cyclophosphamide (CP) is a widely used chemotherapeutic agent but its clinical usefulness is challenged with different forms of toxicities. No studies have evaluated the possible protective effect of nicorandil (NIC) in CP-induced cardiotoxicity. Our study aimed to investigate this effect by using NIC (3 mg/kg/day) orally for 5 days, in the presence or absence of cardiotoxicity induced by intraperitoneal (i.p.) injection of CP (150 mg/kg) on 4th and 5th days. We confirmed the role of ATP-sensitive potassium channel (KATP) by coadministration of glibenclamide (GP) (5 mg/kg/day) 2 h before NIC (3 mg/kg/day) for 5 days. Moreover, the role of endothelial nitric oxide synthase (eNOS) was confirmed by coadministration of nitro-ω-l-arginine (l-NNA) (25 mg/kg/day) for 5 days. Results showed that CP succeeded in induction of cardiotoxicity which manifested by a significant increase in heart weights, creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), troponin I, cardiac tissue malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), interleukin 1β (IL1 β), and caspase-3 levels. Furthermore, CP group showed toxic histopathological changes of marked cardiac damage in addition to a significant decrease in total antioxidant capacity (TAC), superoxide dismutase (SOD), eNOS gene expression, and B cell lymphoma 2 (Bcl2) immunoexpression. NIC succeeded in reversing CP-induced cardiotoxicity by its potassium channel opening effect, stimulating eNOS gene expression, anti-inflammatory, antiapoptotic, and antioxidant properties. Coadministration of GP or l-NNA could diminish the protective effect of NIC. This proves the important role of KATP and eNOS in mediating such protection.
- 1 November 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 95, 223-229
Diacerein inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats
- 1 November 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 95, 223-229
Diacerein inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats
- Open Access
- 16 March 2017
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 31 (4) , 438-446
The role of interleukin‐1b and its antagonist (diacerein) in estradiol benzoate‐induced endometrial hyperplasia and atypia in female rats
Endometrial hyperplasia (EH) is a common gynecological condition and may progress to carcinoma. We investigated the effect of diacerein (DIA) on estradiol benzoate (EB)‐induced EH and atypia. DIA (50 mg/kg/day) was administered orally to rats for 4 weeks, in the presence or absence of EH induced by intramuscular injection of EB (60 μg/100 g) three times per week for 4 weeks. We measured levels of serum total cholesterol, uterine tissue malondialdehyde (MDA), total nitrites (NOx), superoxide dismutase (SOD) activity, caspase‐3, interleukin‐1b (IL‐1b) immunoexpressions, and histopathology. Results showed that EB‐induced EH and atypia manifested by significant increase in serum total cholesterol with increase in MDA and NOxlevels. EB showed the typical histopathological changes of EH and atypia. In addition, there was reduction in SOD activity and decrease in caspase‐3 immunoexpressions but increase in IL‐1b immunoexpressions. DIA was able to reduce EB‐induced pathological changes.
- 16 March 2017
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 31 (4) , 438-446
Open AccessThe role of interleukin‐1b and its antagonist (diacerein) in estradiol benzoate‐induced endometrial hyperplasia and atypia in female rats
Endometrial hyperplasia (EH) is a common gynecological condition and may progress to carcinoma. We investigated the effect of diacerein (DIA) on estradiol benzoate (EB)‐induced EH and atypia. DIA (50 mg/kg/day) was administered orally to rats for 4 weeks, in the presence or absence of EH induced by intramuscular injection of EB (60 μg/100 g) three times per week for 4 weeks. We measured levels of serum total cholesterol, uterine tissue malondialdehyde (MDA), total nitrites (NOx), superoxide dismutase (SOD) activity, caspase‐3, interleukin‐1b (IL‐1b) immunoexpressions, and histopathology. Results showed that EB‐induced EH and atypia manifested by significant increase in serum total cholesterol with increase in MDA and NOxlevels. EB showed the typical histopathological changes of EH and atypia. In addition, there was reduction in SOD activity and decrease in caspase‐3 immunoexpressions but increase in IL‐1b immunoexpressions. DIA was able to reduce EB‐induced pathological changes.